MedTrace Logo

Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection

NCT00844675 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2012-10-18

No results posted yet for this study

Summary

The purpose of this study is:

* To examine if oral administration of Pariet (proton pump inhibitor, 20mg tablets, twice daily for 5 days) before Endoscopic mucosal resection(EMR) exhibits preventive effects of ulcer bleeding compared with placebo group (preoperative administration of placebo)
* To evaluate the effects on the suppression of acid secretion of preoperative administration of an Proton pump inhibitor

Conditions

  • Early Gastric Adenocarcinoma
  • Adenocarcinoma, Tubular

Interventions

DRUG

rabeprazole

The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).

DRUG

placebo

The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    collaborator INDUSTRY

  • The Catholic University of Korea

    lead OTHER

Principal Investigators

  • MyungKu Choi, MD · The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2011-12-31
Completion
2012-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00844675 on ClinicalTrials.gov